News from Shionogi & Co., Ltd. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Oct 05, 2017, 08:01 ET Shionogi To Present S-033188 Phase 3 CAPSTONE-1 Study Results For Treatment Of Influenza At IDWeek 2017 $countyNameToPathMap.put("sp

Shionogi & Co., Ltd. (hereafter "Shionogi") today announced it will report results of a S-033188 Phase 3 study in otherwise healthy influenza...


Oct 04, 2017, 15:20 ET Shionogi Presents Positive Clinical Efficacy Trial Results And In Vitro Data On Cefiderocol, At IDWeek 2017 $countyNameToPathMap.put("sp

Shionogi & Co., Ltd. (hereafter "Shionogi") will present clinical trial efficacy results, as well as supportive in vitro data, on cefiderocol...


Apr 17, 2017, 06:00 ET Shionogi to Present New Data on Cefiderocol (S-649266), a Siderophore Cephalosporin, and S-033188, a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases $countyNameToPathMap.put("sp

Shionogi & Co., Ltd. today announced it will be presenting new data on cefiderocol (S-649266), an investigational siderophore cephalosporin in...


Dec 01, 2016, 00:00 ET Secondary Endpoint Data for S-033188, a Novel Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, Support Favorable Primary Endpoint Data Previously Released $countyNameToPathMap.put("sp

Shionogi & Co., Ltd. (hereafter "Shionogi") presented additional clinical data from a Phase 2 proof-of-concept study for S-033188, a...


Oct 26, 2016, 08:01 ET Cefiderocol, A Novel Investigational Siderophore Cephalosporin, Demonstrated Potent Activity Against Multi-Drug Resistant Gram-Negative Pathogens $countyNameToPathMap.put("sp

Shionogi & Co., Ltd. (hereafter "Shionogi") presented the results of the first global surveillance study for its in-development investigational...


Aug 28, 2016, 21:00 ET Shionogi Presents Results from a Phase 2 Proof-of-Concept Clinical Trial and Non-Clinical Studies of S-033188, a Novel Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza $countyNameToPathMap.put("sp

 Shionogi & Co., Ltd. (hereafter "Shionogi") reported clinical and non-clinical data for S-033188, a cap-dependent endonuclease inhibitor...


Sep 08, 2014, 11:42 ET Shionogi Presents Pre-Clinical and Phase I Results For S-649266, A Novel Siderophore Cephalosporine Antibiotic With Potential To Treat Multidrug-Resistant Gram-Negative Pathogens $countyNameToPathMap.put("sp

 Findings reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) showed Shionogi's novel parenteral...


Feb 17, 2009, 07:08 ET Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity $countyNameToPathMap.put("sp

Shionogi & Co, Ltd. today announced that two distinct year-long studies of velneperit, a novel neuropeptide Y (NPY) Y5 receptor antagonist also...


Aug 27, 2004, 01:00 ET Shionogi Acquires Exclusive Marketing and Distribution Rights for CEDAX(R) (ceftibuten) in the United States $countyNameToPathMap.put("sp

OSAKA, Japan, and FLORHAM PARK, N.J., Aug. 27 /PRNewswire-FirstCall/ -- Shionogi & Co., Ltd., a leading Japanese pharmaceutical company...


Nov 04, 2003, 00:00 ET Shionogi Begins a Novel Glycoprotein Research Effort With Hokkaido University $countyNameToPathMap.put("sp

OSAKA, Japan, Nov. 4 /PRNewswire-FirstCall/ -- Shionogi & Co., Ltd. has entered into a joint research agreement with Professor Shin-ichiro...